Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343(6167):152–157

CAS  PubMed  Article  Google Scholar 

Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L (2019) Distinct dermatomyositis populations are detected with different autoantibody assay platforms. Clin Exp Rheumatol 37(6):1048–1051

PubMed  PubMed Central  Google Scholar 

Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A (2013) Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 52(1):143–154

Article  Google Scholar 

Onishi A, Sugiyama D, Kumagai S, Morinobu A (2013) Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 65(7):1913–1921

PubMed  Article  Google Scholar 

Morrisroe K, Nikpour M (2020) Cancer and scleroderma: recent insights. Curr Opin Rheumatol 32(6):479–487

PubMed  Article  Google Scholar 

Maria ATJ, Partouche L, Goulabchand R, Riviere S, Rozier P, Bourgier C, Le Quellec A, Morel J, Noel D, Guilpain P (2018) Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors. Front Immunol 9:3112

CAS  PubMed  Article  Google Scholar 

Shah AA, Casciola-Rosen L, Rosen A (2015) Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 67(2):317–326

CAS  PubMed  PubMed Central  Article  Google Scholar 

Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16(1):R53

PubMed  PubMed Central  Article  Google Scholar 

Colaci M, Giuggioli D, Vacchi C, Lumetti F, Iachetta F, Marcheselli L, Federico M, Ferri C (2014) Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. Autoimmun Rev 13(2):132–137

PubMed  Article  Google Scholar 

Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 62(9):2787–2795

PubMed  PubMed Central  Article  Google Scholar 

Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W (2011) Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 13(6):R211

CAS  PubMed  PubMed Central  Article  Google Scholar 

Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F (2011) Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 38(7):1329–1334

CAS  PubMed  Article  Google Scholar 

Aozasa N, Miyazaki M, Hayakawa J, Tamaki T, Hamaguchi Y, Sato S, Asano Y (2020) Case of systemic sclerosis with multiple primary malignancies in whom anti-RNA polymerase III antibody was detected by immunoprecipitation. J Dermatol 47(7):e269–e270

PubMed  Article  Google Scholar 

Xu GJ, Shah AA, Li MZ, Xu Q, Rosen A, Casciola-Rosen L, Elledge SJ (2016) Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer. Proc Natl Acad Sci USA 113(47):E7526–E7534

CAS  PubMed  PubMed Central  Google Scholar 

Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ, Casciola-Rosen L (2017) Brief report: anti-RNPC-3 antibodies as a marker of cancer-associated scleroderma. Arthritis Rheumatol 69(6):1306–1312

CAS  PubMed  PubMed Central  Article  Google Scholar 

Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K (2017) Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. Clin Exp Rheumatol 35(Suppl 106):71–74

PubMed  PubMed Central  Google Scholar 

Betteridge ZE, Priest L, Cooper RG, McHugh NJ, Blackhall F, Lamb JA (2018) Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. Arthritis Res Ther 20(1):176

PubMed  PubMed Central  Article  CAS  Google Scholar 

Partouche L, Goulabchand R, Maria ATJ, Riviere S, Jorgensen C, Rigau V, Bourgier C, Bessis D, Le Quellec A, Quere I, Morel J, Guilpain P (2020) Biphasic temporal relationship between cancers and systemic sclerosis: a clinical series from Montpellier University Hospital and review of the literature. J Clin Med 9(3):853

PubMed Central  Article  Google Scholar 

Shah AA, Laiho M, Rosen A, Casciola-Rosen L (2019) Protective effect against cancer of antibodies to the large subunits of both RNA polymerases I and III in scleroderma. Arthritis Rheumatol 71(9):1571–1579

CAS  PubMed  PubMed Central  Article  Google Scholar 

Shah AA, Rosen A (2011) Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 23(6):530–535

PubMed  PubMed Central  Article  Google Scholar 

Mecoli CA, Adler BL, Yang Q, Hummers LK, Rosen A, Casciola-Rosen L, Shah AA (2021) Cancer in systemic sclerosis: analysis of antibodies against components of the Th/To complex. Arthritis Rheumatol 73(2):315–323

CAS  PubMed  Article  Google Scholar 

Watad A, McGonagle D, Bragazzi NL, Tiosano S, Comaneshter D, Shoenfeld Y, Cohen AD, Amital H (2019) Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. Oncoimmunology 8(6):e1588084

PubMed  PubMed Central  Article  Google Scholar 

Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM (2015) Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol 67(4):1053–1061

CAS  PubMed  PubMed Central  Article  Google Scholar 

Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, Rosen A, Shah AA (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77(8):1179–1186

PubMed  Google Scholar 

Stertz G (1916) Polymyositis. Berl Klin Wochenschr 53:489

Google Scholar 

Kankeleit H (1916) Über primaire nichteitrige polymyositis. Dtsch Arch Klin Med 120:335–339

Google Scholar 

Airio A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22(7):1300–1303

CAS  PubMed  Google Scholar 

Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6(1):9–13

CAS  PubMed  Article  Google Scholar 

Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis: A population-based study. N Engl J Med 326(6):363–367

CAS  PubMed  Article  Google Scholar 

Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100

CAS  PubMed  Article  Google Scholar 

Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg 21(2):131–136

PubMed  Article  Google Scholar 

Di Rollo D, Abeni D, Tracanna M, Capo A, Amerio P (2014) Cancer risk in dermatomyositis: a systematic review of the literature. G Ital Dermatol Venereol 149(5):525–537

PubMed  Google Scholar 

Madan V, Chinoy H, Griffiths CE, Cooper RG (2009) Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 34(4):451–455

CAS  PubMed  Article  Google Scholar 

Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70(6):360–374

CAS  Article  Google Scholar 

Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, Matsushita T, Orito H, Hamaguchi Y, Yanaba K, Itoh M, Asano Y, Seishima M, Ogawa F, Sato S, Takehara K (2007) Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46(1):25–28

CAS  PubMed  Article  Google Scholar 

Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, Miller FW, Rider LG (2006) A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 54(11):3682–3689

CAS  PubMed  Article  Google Scholar 

Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N, Ueda-Hayakawa I, Asano Y, Ogawa F, Fujikawa K, Miyagi T, Mabuchi E, Hirose K, Akimoto N, Hatta N, Tsutsui K, Higashi A, Igarashi A, Seishima M, Hasegawa M, Takehara K (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64(2):513–522

CAS  PubMed  Article